Limited-stage small-cell lung cancer: therapeutic options
Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, i.e., limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every...
Gespeichert in:
| Veröffentlicht in: | Oncology (Williston Park, N.Y.) N.Y.), 2007-03, Vol.21 (3), p.303-12; discussion 312 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12; discussion 312 |
|---|---|
| container_issue | 3 |
| container_start_page | 303 |
| container_title | Oncology (Williston Park, N.Y.) |
| container_volume | 21 |
| creator | Ganti, Apar Kishor Zhen, Weining Kessinger, Anne |
| description | Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, i.e., limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease. |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70399021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A161431609</galeid><sourcerecordid>A161431609</sourcerecordid><originalsourceid>FETCH-LOGICAL-g344t-6b692ed5c081ca1f341b9ef5177a220114ffcccce96060e72ed706c3eaf24b503</originalsourceid><addsrcrecordid>eNptkU1PwzAMhnsAsTH4C6jisFtR0qTJwm2a-JImcYFzlaZOlylNSpMe-PcEBhKg2QdL1vNar-2TbI5WAhUCCTzLzkPYI1QyhlZn2QxzSjklbJ6JrelNhLYIUXaQh15aWyiwNreT63IlnYLxNo87GOUAUzQq90M03oWL7FRLG-Dyuy6y1_u7l81jsX1-eNqst0VHKI0Fa5gooa0UWmElsSYUNwJ0hTmXZYkwplqrFCAYYgh4YjliioDUJW0qRBbZ8jB3GP3bBCHWvQmfDqUDP4WaIyIEKnECr_-Bez-NLnmrsahoVTHKE1QcoE5aqI3TPo5SdeDSftY70Ca115hhSjBDIvE3R_iULfRGHRUsfwl2IG3cBW-nr5v9Ba--7U5ND209jKaX43v98xvyAfhZhug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195455647</pqid></control><display><type>article</type><title>Limited-stage small-cell lung cancer: therapeutic options</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ganti, Apar Kishor ; Zhen, Weining ; Kessinger, Anne</creator><creatorcontrib>Ganti, Apar Kishor ; Zhen, Weining ; Kessinger, Anne</creatorcontrib><description>Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, i.e., limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.</description><identifier>ISSN: 0890-9091</identifier><identifier>PMID: 17447436</identifier><language>eng</language><publisher>United States: Intellisphere, LLC</publisher><subject>Andrew T Turrisi, MD ; Anne Kessinger, MD ; Cancer ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - radiotherapy ; Carcinoma, Small Cell - surgery ; Carcinoma, Small Cell - therapy ; Care and treatment ; Diagnosis ; Humans ; Lung cancer ; Lung cancer, Small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Lung Neoplasms - surgery ; Lung Neoplasms - therapy ; Methods ; R, Feld ; R, Pignon JP ; Tumor staging ; WK, Evans</subject><ispartof>Oncology (Williston Park, N.Y.), 2007-03, Vol.21 (3), p.303-12; discussion 312</ispartof><rights>COPYRIGHT 2007 Intellisphere, LLC</rights><rights>Copyright 2007 CMP Media LLC. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17447436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ganti, Apar Kishor</creatorcontrib><creatorcontrib>Zhen, Weining</creatorcontrib><creatorcontrib>Kessinger, Anne</creatorcontrib><title>Limited-stage small-cell lung cancer: therapeutic options</title><title>Oncology (Williston Park, N.Y.)</title><addtitle>Oncology (Williston Park)</addtitle><description>Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, i.e., limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.</description><subject>Andrew T Turrisi, MD</subject><subject>Anne Kessinger, MD</subject><subject>Cancer</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Carcinoma, Small Cell - surgery</subject><subject>Carcinoma, Small Cell - therapy</subject><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung cancer, Small cell</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Lung Neoplasms - surgery</subject><subject>Lung Neoplasms - therapy</subject><subject>Methods</subject><subject>R, Feld</subject><subject>R, Pignon JP</subject><subject>Tumor staging</subject><subject>WK, Evans</subject><issn>0890-9091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkU1PwzAMhnsAsTH4C6jisFtR0qTJwm2a-JImcYFzlaZOlylNSpMe-PcEBhKg2QdL1vNar-2TbI5WAhUCCTzLzkPYI1QyhlZn2QxzSjklbJ6JrelNhLYIUXaQh15aWyiwNreT63IlnYLxNo87GOUAUzQq90M03oWL7FRLG-Dyuy6y1_u7l81jsX1-eNqst0VHKI0Fa5gooa0UWmElsSYUNwJ0hTmXZYkwplqrFCAYYgh4YjliioDUJW0qRBbZ8jB3GP3bBCHWvQmfDqUDP4WaIyIEKnECr_-Bez-NLnmrsahoVTHKE1QcoE5aqI3TPo5SdeDSftY70Ca115hhSjBDIvE3R_iULfRGHRUsfwl2IG3cBW-nr5v9Ba--7U5ND209jKaX43v98xvyAfhZhug</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Ganti, Apar Kishor</creator><creator>Zhen, Weining</creator><creator>Kessinger, Anne</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200703</creationdate><title>Limited-stage small-cell lung cancer: therapeutic options</title><author>Ganti, Apar Kishor ; Zhen, Weining ; Kessinger, Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g344t-6b692ed5c081ca1f341b9ef5177a220114ffcccce96060e72ed706c3eaf24b503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Andrew T Turrisi, MD</topic><topic>Anne Kessinger, MD</topic><topic>Cancer</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Carcinoma, Small Cell - surgery</topic><topic>Carcinoma, Small Cell - therapy</topic><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung cancer, Small cell</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Lung Neoplasms - surgery</topic><topic>Lung Neoplasms - therapy</topic><topic>Methods</topic><topic>R, Feld</topic><topic>R, Pignon JP</topic><topic>Tumor staging</topic><topic>WK, Evans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganti, Apar Kishor</creatorcontrib><creatorcontrib>Zhen, Weining</creatorcontrib><creatorcontrib>Kessinger, Anne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology (Williston Park, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganti, Apar Kishor</au><au>Zhen, Weining</au><au>Kessinger, Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limited-stage small-cell lung cancer: therapeutic options</atitle><jtitle>Oncology (Williston Park, N.Y.)</jtitle><addtitle>Oncology (Williston Park)</addtitle><date>2007-03</date><risdate>2007</risdate><volume>21</volume><issue>3</issue><spage>303</spage><epage>12; discussion 312</epage><pages>303-12; discussion 312</pages><issn>0890-9091</issn><abstract>Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, i.e., limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.</abstract><cop>United States</cop><pub>Intellisphere, LLC</pub><pmid>17447436</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-9091 |
| ispartof | Oncology (Williston Park, N.Y.), 2007-03, Vol.21 (3), p.303-12; discussion 312 |
| issn | 0890-9091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70399021 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Andrew T Turrisi, MD Anne Kessinger, MD Cancer Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - radiotherapy Carcinoma, Small Cell - surgery Carcinoma, Small Cell - therapy Care and treatment Diagnosis Humans Lung cancer Lung cancer, Small cell Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Lung Neoplasms - surgery Lung Neoplasms - therapy Methods R, Feld R, Pignon JP Tumor staging WK, Evans |
| title | Limited-stage small-cell lung cancer: therapeutic options |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T13%3A34%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limited-stage%20small-cell%20lung%20cancer:%20therapeutic%20options&rft.jtitle=Oncology%20(Williston%20Park,%20N.Y.)&rft.au=Ganti,%20Apar%20Kishor&rft.date=2007-03&rft.volume=21&rft.issue=3&rft.spage=303&rft.epage=12;%20discussion%20312&rft.pages=303-12;%20discussion%20312&rft.issn=0890-9091&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA161431609%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195455647&rft_id=info:pmid/17447436&rft_galeid=A161431609&rfr_iscdi=true |